Novo Nordisk has initiated a Phase I clinical trial of GlycoPEGylated Factor VIIa, a long-acting version of NovoSeven Coagulation Factor VIIa, triggering an undisclosed milestone payment to Neose Technologies, Inc. under the companies’ license agreement. The trial will assess the safety and pharmacokinetics of GlycoPEGylated Factor VIIa in healthy volunteers. “Novo Nordisk is committed to developing therapies to prevent or reduce bleeding episodes and to improve the quality of l...